• English
  • தமிழ்
  • বাংলা
  • മലയാളം
  • ગુજરાતી
  • हिंदी
  • मराठी
  • Business

The Financial Express

  • Whatsapp Whatsapp Link
  • Facebook Facebook Link
  • Twitter Twitter Link
  • Linkedin Linkedin Link
Google News Follow
Watchlist
  • Home
  • Business
  • Markets
  • Market Stats
  • Mutual Funds
  • Money
  • India News
  • Tech
  • US News
  • Shorts
  • ePaper
  • Defence Stocks
  • AI Stocks
  • MF Screener
  • Finance Stocks
  • IT Stocks
  • Gold Rate
  • Silver Rate
  • Breakout Stocks
  • Home
  • Market
    • Stock Insights
    • Cryptocurrency
    • IPO News
    • Stock Market Quotes
    • Indices
    • Nifty 50
    • Sensex
    • Top Gainers
    • Top Losers
    • IPO Stats
  • Market Dashboard
  • Commodities
    • Gold Rate in India
    • Silver Rate in India
    • Petrol Rate in India
    • Diesel Rate in India
  • Opportunity Abroad
  • Money
    • Insurance
    • Income Tax
    • Mutual Funds News
    • MF Screener
  • Economy
  • Business
    • Brand Wagon
    • SME
    • Defence
    • Healthcare
  • Industry
    • Banking & Finance
  • India News
  • World News
  • Trending News
  • Jobs-Career
  • Infrastructure
    • Railways
    • Aviation
    • Roadways
  • Auto
  • Life
    • Lifestyle
    • Entertainment
    • Technology
    • Travel & Tourism
    • Science
  • Sports
  • Opinion
  • Multimedia
    • Photos
    • Web Stories
  • Events
  • ePaper
  • Today’s Paper
  • About us
  • PRIVACY POLICY
  • TERMS AND CONDITIONS
  • Contact Us

  1. Business News
  2. About
  3. pharmaceutical

pharmaceutical

  • Click to share on Twitter (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
Indian Pharma Starts FY27 Strong, But Margin Softening Looms Amid US Generics Drag: Ind-Ra
Pharma sector growth stays strong in FY27; margins to soften as costs escalate: Ind-Ra

India Ratings expects domestic pharma growth of ~10% in FY27, though US market weakness and rising input/logistics costs may weigh…

August 19, 2026 18:50 IST
**Natco Pharma shares fall 6% after Q1 profit plunges 57%; Rs 1.50 interim dividend announced**
Natco Pharma shares fall 6% after Q1 profit plunges 57%; Rs 1.50 interim dividend announced

Natco Pharma shares fell 6% as Q1 profit dropped 57% on lower lenalidomide revenue; firm set a Rs 1.50 dividend.…

August 14, 2026 15:07 IST
GLP-1 drugs, new launches lift India pharma growth in July
India pharma rebounds with Sun, Zydus leading an overall 12.1% growth in July

India’s pharma July sales rise 12.1% on higher prices, new launches and rising GLP-1 demand.

August 13, 2026 14:02 IST
40% Growth, 50% more revenue per employee: The IT company that doesn’t look like an IT company

India’s IT slowdown has created an unlikely outperformer. A niche business model, sticky clients and AI-led transformation are driving growth,…

August 6, 2026 05:04 IST
A financial graphic focusing on the Nifty Healthcare Index breakout, showing technical chart setups for Torrent Pharma, Apollo Hospitals, Divi's Labs, and Mankind Pharma supporting the move towards 17,600, against a backdrop of a strong bullish weekly candle.
Monday Watchlist: Will short-covering extend Nifty’s rally? Torrent Pharma, Apollo Hospitals in focus

Nifty’s short-covering rally may extend as Metal and Healthcare flash bullish setups; watch Torrent Pharma, Apollo and key levels Monday.

August 3, 2026 05:30 IST
How Trump’s Proposed 200% Generic Drug Tariffs Could Push Indian Pharma Up the Value Chain
A potential blessing in disguise for pharma

Trump’s threat of 200% tariffs on generics may well encourage Indian firms to invest further in the US with focus…

July 31, 2026 00:04 IST
Torrent Pharma Q1 results: Net profit up 3%, revenue surges 55%
Torrent Pharma Q1 results: Net profit up 3%, revenue surges 55% 

Torrent Pharma Q1 profit rose 3% to Rs 566 crore as revenue jumped 55% and EBITDA climbed 61%; see key…

July 30, 2026 18:56 IST
Cipla vs Dr Reddy Q1 FY27 earnings and US pipeline comparison
Cipla Vs Dr. Reddy’s: Which pharma giant offers better risk-reward as spotlight shifts to US pipeline 

Cipla and Dr. Reddy’s entered FY27 on different trajectories. While Cipla posted record quarterly revenue backed by respiratory growth, Dr.…

Updated: July 29, 2026 13:08 IST
Biocon expands biosimilar portfolio
Biocon gets Canada government’s nod for Yesintek autoinjector to treat autoimmune diseases

Biocon wins Health Canada approval for Yesintek autoinjector, expanding autoimmune biosimilar options in Canada. Read more.

July 29, 2026 10:35 IST
House panel seeks curbs on ‘non-scheduled’ drug prices

A parliamentary panel urges tighter regulation on non-scheduled medicines in India, highlighting major price control gaps and widespread profiteering in…

July 29, 2026 01:16 IST
Technical candlestick analysis chart showing Nifty Financial Services Index testing pattern support near 25,300 and Nifty Pharma Index approaching a crucial rising trendline support around 25,350.
Monday Watchlist: Smart Money vs Retail — Will Nifty bounce as pharma, financials test support?

Nifty eyes an expiry bounce as FIIs stay heavily short and pharma, financials test key supports; watch 25,300 breaks for…

July 27, 2026 05:30 IST
Trump's proposed generic drug tariffs and Indian pharma outlook by Bernstein
Why Trump’s tariff plan may more likely benefit Indian pharma than hurt? Bernstein explains

Bernstein says Trump’s proposed tariffs on generic medicines may create near-term uncertainty, but large Indian drugmakers remain well positioned for…

July 23, 2026 15:20 IST
A financial trading screen showing Dr. Reddy’s Laboratories' stock price declining 7% to a 52-week low on the NSE. The interface overlays key Q1FY27 financial metrics, including a 69% YoY drop in net profit, a ₹240 crore Semaglutide API inventory provision, and EBITDA margin contraction to 10%.
Dr Reddy’s slides to 52-week low: Brokerages slash price target on Semaglutide API, Middle East concerns

Dr Reddy’s hits a 52-week low after weak Q1 earnings, Semaglutide API issues and Middle East costs trigger target cuts;…

July 23, 2026 10:53 IST
US tariff threat keeps drugmakers on their toes

Move may unravel given US consumers’ reliance on India’s low-cost generics, analysts feel

July 22, 2026 22:08 IST
Dr Reddy’s Q1FY27: Net Profit declines 69% YoY, impacted by Rs 239 crore semaglutide provisions
Dr Reddy’s Q1FY27: Net Profit declines 69% YoY, impacted by Rs 239 crore  semaglutide provisions 

Dr Reddy’s Q1FY27 net profit fell 69% YoY to Rs 443.5 crore, hit by Rs 239.7 crore semaglutide API provisions;…

Updated: July 22, 2026 17:14 IST
US tariff & reshoring: Indian pharma debates impact of 3x rise in US drug-making costs
US tariff & reshoring: Indian pharma debates impact of 3x rise in US drug-making costs 

Since higher cost of operations is a major deterrent at the moment, Indian pharma companies see the likely implications in…

Updated: July 22, 2026 13:15 IST
A financial trading terminal displaying the Nifty Pharma Index drop alongside a visual timeline breakdown of Donald Trump's phased tariff policy on generic drug imports—showing 0% duty until August 2028, 100% in 2028–2029, and 200% from August 2029 onward.
Pharma stocks fall after Trump’s 200% tariff announcement for generic imports: Experts decode what it means

Track pharma stocks as Trump’s phased US tariff plan hits sentiment, though analysts say India’s cost edge may cushion generic…

July 22, 2026 10:36 IST
A clean, modern financial analytics visual depicting Motilal Oswal's initiation of coverage on Emcure Pharma with a 'Buy' rating. The interface displays a target price of ₹2,260 representing over 27% upside, alongside projected 3-year CAGR growth metrics: 14% revenue, 20% EBITDA, and 28% PAT over FY26-28.
Emcure Pharma: Motilal Oswal initiates coverage, sees 27% upside on multi-engine growth opportunity

Track Emcure Pharma as Motilal Oswal starts Buy with a ₹2,260 target, citing 27% upside and multi-engine growth across chronic,…

July 21, 2026 13:08 IST
  • Next »

Related News

Man earns Rs 30 lakh salary, doesn't file ITR; Income Tax Dept slaps Rs 3.74 lakh penalty — what ITAT said
Man earns Rs 30 lakh salary, doesn’t file ITR; Income Tax Dept slaps Rs 3.74 lakh penalty — what ITAT said
Chennai Egmore, Chennai Egmore Railway Station, Southern Railway, Indian Railways, Railway News, Chennai Trains, Train Services, Railway Redevelopment, Tambaram, Mambalam, Chennai Beach
Chennai Egmore redevelopment: Southern Railway announces changes in train services- Check dates, routes, timings and more
NEET-PG-2026
NEET-PG 2026: Single-shift exam, less travel hassle as Centre announces key reforms 
Zoho founder Sridhar Vembu flags 'job crisis' in India.
‘Very uncertain global landscape’: Zoho’s Sridhar Vembu sounds stark warning about ‘job crisis’ in India
Prime Minister Narendra Modi.
‘Want to forgive children who abused me’: PM Modi issues appeal for ‘misguided’ youth in video message
shorts
Explainer: Muse Glimmer – What Meta’s new AI model means
Explainer: Muse Glimmer – What Meta’s new AI model means
Technology3 hr ago

Meta has launched Muse Glimmer, a 30-billion-parameter AI model that can operate on a laptop or single consumer GPU, eliminating the need for cloud servers. This open-weight model can be downloaded, modified, and used to build applications. CEO Rishi Raj states that this aims to reduce reliance on the cloud and compete with Chinese firms.

View all shorts

Trending Topics

defence stocks
Gold rate today
Silver rate today
AI stocks
mutual funds
semiconductor stocks

Top Categories
  • Market
  • India News
  • Stock Insights
  • Money
  • Opportunities Abroad
  • World News
  • Latest News
  • Technology
  • ITR Guide
  • Money Insights
Stock Screeners
  • Stock Screener
  • Break Out Stocks
  • Defence Stocks
  • Consistently Growing Stocks
  • Low Price Blue Chip Stocks
Top NSE/BSE Companies Share Price
  • Tata Motors share price
  • Tata Steel share price
  • State Bank Of India share price
  • HDFC Bank share price
  • Infosys share price
  • ITC share price
  • Wipro share price
  • NTPC share price
  • ongc share price
  • Adani Enterprises share price
  • Adani Ports and Special Economic Zone share price
  • Bharat Petroleum Corporation share price
  • Coal India share price
  • Bajaj Finance share price
  • ICICI Bank share price
  • Titan Company share price
  • Larsen & Toubro share price
  • Power Grid Corporation Of India share price
  • Asian Paints share price
Gold Price in Top Metro Cities
  • Gold Rate Today
  • Gold Rate in Dubai
  • Gold Rate in Chennai
  • Gold Rate in Kerala
  • Gold Rate in Hyderabad
  • Gold Rate in Bangalore
  • Gold Rate in Mumbai
  • Gold Rate in Noida
  • Gold Price in Delhi
  • Gold Price in Ahmedabad
  • Gold Price in Kolkata
Latest News
  • US Treasury doubles long-term bond buybacks to $4 billion: What will change from September 9
  • 300mn jobs exposed: Inside Goldman Sachs’ AI labour market warning
  • US proposes new rules for 4 refundable tax credits: What changes for immigrants?
  • Chennai Egmore redevelopment: Southern Railway announces changes in train services- Check dates, routes, timings and more
  • Mumbai’s Sion Bridge work expedited: BMC targets September 30 completion, 5 months ahead of schedule
Follow Us
  • Facebook Facebook Link
  • Twitter Twitter Link
  • Linkedin Linkedin Link
Download Apps
  • Play_stor Play_stor Link
  • Apple_stor Apple_stor Link
Indian Express Group
  • INDIAN EXPRESS GROUP
  • The Indian Express
  • Loksatta
  • Jansatta
  • Inuth
  • Ramnath Goenka Awards
  • IE Tamil
  • IE Malayalam
  • IE Bangla
  • IE Gujarati
  • This website follows the DNPA’s code of conduct
Quick Links
  • T&C
  • Privacy Policy
  • CONTACT US
  • About Us
Copyright © 2026 The Indian Express [P] Ltd. All Rights Reserved
Market Pulse